Dexcom reports Q4 revenue of $1.26 billion, provides 2026 outlook

Go back to Dexcom reports Q4 revenue of $1.26 billion, provides 2026 outlook

Jefferies on DexCom (DXCM): 'We think the '26 guide is conservative, leaving room for upside in stock'

January 12, 2026 10:45 AM EST

Jefferies analyst Matthew Taylor reiterated a Buy rating and $112.00 price target on DexCom (NASDAQ: DXCM).

The analyst comments "DXCM reported prelim 4Q25 sales of $1.26B +13% vs cons $1.24B, better than some feared. In '26, DXCM is guiding to an initial range of... More